The Experts below are selected from a list of 297 Experts worldwide ranked by ideXlab platform

Jorge E. Cortes - One of the best experts on this subject based on the ideXlab platform.

  • Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
    2017
    Co-Authors: Jorge E. Cortes
    Abstract:

    This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed Chronic Myeloid Leukemia patients.

  • Chronic Myeloid Leukemia: reminiscences and dreams
    Haematologica, 2016
    Co-Authors: Tariq I. Mughal, Jorge E. Cortes, M W Deininger, Jerald P. Radich, Jane F. Apperley, Timothy P. Hughes, Christine J. Harrison, Carlo Gambacorti-passerini, Giuseppe Saglio, George Q. Daley
    Abstract:

    With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of Chronic Myeloid Leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of Chronic Myeloid Leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman originally made seminal contributions to the use of autologous and allogeneic stem cell transplantation from the late 1970s onwards. Then, in collaboration with Brian Druker, he led efforts to develop ABL1 tyrosine kinase inhibitors for the treatment of patients with Chronic Myeloid Leukemia in the late 1990s. He also led the global efforts to develop and harmonize methodology for molecular monitoring, and was an indefatigable organizer of international conferences. These conferences brought together clinicians and scientists, and accelerated the adoption of new therapies. The abundance of praise, tributes and testimonies expressed by many serve to illustrate the indelible impressions these two passionate and affable scholars made on so many people’s lives. This tribute provides an outline of the remarkable story of Chronic Myeloid Leukemia, and in writing it, it is clear that the historical triumph of biomedical science over this Leukemia cannot be considered without appreciating the work of both Janet Rowley and John Goldman.

  • Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
    Expert review of hematology, 2016
    Co-Authors: Yasmin Rosshandler, Ann Q. Shen, Jorge E. Cortes, Hanna Jean Khoury
    Abstract:

    Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of Chronic Myeloid Leukemia in Chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in Chronic Myeloid Leukemia, especially in the Chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory Chronic Myeloid Leukemia.

  • Novel therapies for patients with Chronic Myeloid Leukemia.
    Expert review of anticancer therapy, 2004
    Co-Authors: Francis J. Giles, Hagop M. Kantarjian, Jorge E. Cortes
    Abstract:

    The most immediate issues that will have a major impact on the long-term survival of patients with Chronic Myeloid Leukemia is the optimal use of imatinib mesylate (Gleevec, Novartis) and the development of effective therapies for those patients who are intolerant of, or become resistant to, optimal doses of this agent. Of the multiple new agents that are currently being developed for patients with Chronic Myeloid Leukemia, most are being investigated in patients who have developed resistance to imatinib, which is a confounding factor in itself. The mechanisms of action of novel agents are diverse and they may have a variably synergistic therapeutic relationship with imatinib. The complete blockade of the intracellular pathways that are triggered by Bcr-Abl, combined with successful reversal of apoptotic and/or angiogenic abnormalities in Chronic Myeloid Leukemia, may well lead to a cure for the majority of patients.

Hanna Jean Khoury - One of the best experts on this subject based on the ideXlab platform.

  • Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
    Expert review of hematology, 2016
    Co-Authors: Yasmin Rosshandler, Ann Q. Shen, Jorge E. Cortes, Hanna Jean Khoury
    Abstract:

    Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of Chronic Myeloid Leukemia in Chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in Chronic Myeloid Leukemia, especially in the Chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory Chronic Myeloid Leukemia.

Yaoyu Chen - One of the best experts on this subject based on the ideXlab platform.

  • Omacetaxine mepesuccinate in the treatment of intractable Chronic Myeloid Leukemia.
    OncoTargets and therapy, 2014
    Co-Authors: Yaoyu Chen
    Abstract:

    In a significant proportion of patients with Chronic Myeloid Leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of Leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Omacetaxine mepesuccinate has been recently approved by the US Food and Drug Administration to treat patients with Chronic Myeloid Leukemia who failed to respond to multiple tyrosine kinase inhibitors and/or acquired the BCR-ABL-T315I mutation. In this review, we discuss the use and effectiveness of omacetaxine mepesuccinate in the treatment of Chronic Myeloid Leukemia, with coverage of its pharmacology, mode of action, and pharmacokinetics. We believe that omacetaxine mepesuccinate will be beneficial to many patients with Chronic Myeloid Leukemia who do not respond well to tyrosine kinase inhibitors.

Yasmin Rosshandler - One of the best experts on this subject based on the ideXlab platform.

  • Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia
    Expert review of hematology, 2016
    Co-Authors: Yasmin Rosshandler, Ann Q. Shen, Jorge E. Cortes, Hanna Jean Khoury
    Abstract:

    Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of Chronic Myeloid Leukemia in Chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in Chronic Myeloid Leukemia, especially in the Chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory Chronic Myeloid Leukemia.

Raj Kumar Singh - One of the best experts on this subject based on the ideXlab platform.

  • Oxidative stress and antioxidant status in patients with Chronic Myeloid Leukemia.
    Indian journal of clinical biochemistry : IJCB, 2008
    Co-Authors: Rizwan Ahmad, Anil Kumar Tripathi, Payal Tripathi, Ranjana Singh, Sushma Singh, Raj Kumar Singh
    Abstract:

    Chronic Myeloid Leukemia is a myeloproliferative disorder with a unique rearrangement, the Philadelphia chromosome. Oxidative stress, a pervasive condition of an increased number of reactive oxygen species, is now recognized to be prominent feature of various diseases and their progression. Thus antioxidants, which control the oxidative stress state, represent a major line of defense regulating overall true state of health. The relationship between antioxidants status and levels of well-known markers of oxidative stress that are measured as lipid peroxides and oxidized proteins reflect better health indices and postures. The aim of this study was to evaluate the role of oxidative stress in pathophysiology of Chronic Myeloid Leukemia by measuring the circulating plasma lipid peroxide levels in terms of malonyldialdehyde, total lipid hydroperoxide and oxidized proteins as protein carbonyl whereas antioxidant status were estimated in terms of reduced glutathione and total thiol in plasma of Chronic Myeloid Leukemia patients. The present study included 47 Chronic Myeloid Leukemia patients and 20 age-and sex-matched healthy subjects. Out of 47 Chronic Myeloid Leukemia patients, 31 were in Chronic phase (CML-CP) and 16 in accelerated phase (CML-AP). The median age of Chronic Myeloid Leukemia patients was 33 years and that of controls was 32 years. Oxidative stress and antioxidant status in plasma were evaluated by spectrophotometric procedures. There was a significant increase (p